|
End-of-day quote
Nasdaq
29/09/2026
|
5-day change | 1st Jan Change | ||
| 15.92 USD | -1.67% |
|
-0.44% | +22.18% |
| 09-30 | Abbott Launches SimpleScreen Blood Test for Colorectal Cancer | MT |
| 09-21 | Freenome, Inc.(NasdaqCM:FRNM) added to S&P TMI Index | CI |
Evolution of the Average Target: Freenome, Inc.
Evolution of the Target Price: Freenome, Inc.
Changes in Analyst Recommendations: Freenome, Inc.
a3456af5433fa.DEpUTrgJo21bMprN2zd0HnpaGK77vXu6l0hhgbauW0Y.PHwDC9NilhViYOCarURFdBZsNenK2TDQ7SUU9-HYPi1VIjYY1ljSFBoA2w~5e4610369ac798efc8900449a19080f6
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | +10.29% | |||
| +11.79% | |||||
| +27.75% | |||||
| +21.67% | |||||
| +24.6% | |||||
| +11.82% | |||||
| +21.07% | |||||
| +46.63% | |||||
| +6.77% | |||||
| +20.91% | |||||
| Average | +20.33% | |||||
| Weighted average by Cap. | +20.68% |
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.32USD
Average target price
18.00USD
Spread / Average Target
+10.29%
High Price Target
21.00USD
Spread / Highest target
+28.68%
Low Price Target
17.00USD
Spread / Lowest Target
+4.17%
Analyst Consensus Detail
Consensus revision (last 18 months)
- Stock Market
- Stocks
- FRNM Stock
- Consensus Freenome, Inc.
Select your edition
All financial news and data tailored to specific country editions
